Invention Grant
US08486401B2 Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
有权
结合TrkA并作为NGF拮抗剂分子的单克隆抗体及其用于治疗由NGF诱导的疼痛的用途
- Patent Title: Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
- Patent Title (中): 结合TrkA并作为NGF拮抗剂分子的单克隆抗体及其用于治疗由NGF诱导的疼痛的用途
-
Application No.: US12557825Application Date: 2009-09-11
-
Publication No.: US08486401B2Publication Date: 2013-07-16
- Inventor: Michal M. Novak
- Applicant: Michal M. Novak
- Applicant Address: IT Rome
- Assignee: Lay Line Genomics S.p.A.
- Current Assignee: Lay Line Genomics S.p.A.
- Current Assignee Address: IT Rome
- Agency: Saul Ewing LLP
- Agent Peter C. Lauro, Esq.
- Priority: ITRM99A0333 19990526
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12P21/08 ; A61K39/00 ; A61K39/395 ; A61K49/00 ; A61K49/16 ; G01N33/53
Abstract:
Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognise the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.
Public/Granted literature
Information query
